Human chemokine Alpha-3 polypeptides and DNA (RNA) encoding such chemotactic
cytokines and a procedure for producing such polypeptides by recombinant techniques
is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines
for the treatment of leukemia, tumors, chronic infections, auto-immune disease,
fibrotic disorders, sepsis, wound healing and psoriasis and to stimulate stem cell
mobilization. Antagonists against such chemotactic cytokines and their use as a
therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory
and infective diseases, allergic reactions, prostaglandin-independent fever, ARDS
and bone marrow failure are also disclosed. Also disclosed are diagnostic assays
for detecting diseases related to mutations in the nucleic acid sequences and altered
concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting
mutations in the polynucleotides encoding the chemotactic cytokines and for detecting
altered levels of the polypeptide in a host.
